NCT05775289 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05775289
Title	A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Hoffmann-La Roche
Indications	lung non-small cell carcinoma
Therapies	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ITA \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS

Additional content available in CKB BOOST